文献速递腹部儿科影像骨肌CTMR

mTOR抑制剂治疗结节性硬化症:腹部CT/MRI纵向评估肌肉质量

mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI.
PubMed 文献 · Radiol Imaging Cancer · 2020-09-18

回顾性纳入24例接受mTOR抑制剂的结节性硬化症患者,基于129次腹部CT或MRI测量L3水平腰大肌横截面积。提示慢性mTOR抑制似乎不与肌少症相关。

要点

  • L3水平腰大肌横截面积可在腹部CT/MRI上用于纵向评估肌肉质量。

关键影像表现/征象

  • 于L3水平勾画腰大肌感兴趣区测量横截面积。
  • 共分析129次腹部CT或MRI检查。

诊断标准与关键数值

  • 末次检查时mTOR抑制中位疗程106个月(范围1310-3717天)。

临床应用与阅片要点

  • 腹部CT/MRI阅片时可于L3水平测量腰大肌横截面积以纵向评估肌肉质量。
  • 在结节性硬化症患者中,腰大肌面积变化需结合身高因素解读。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine the effect of chronic mammalian target of rapamycin (mTOR) inhibition on skeletal muscle mass in patients with tuberous sclerosis complex (TSC).

MATERIALS AND METHODS: In this retrospective study, patients with TSC who were taking mTOR inhibitors and who underwent at least two abdominal CT or MRI examinations between 2005 and 2017 were included (n = 24; 14 males; mean age, 14.5 years ± 7.8 [standard deviation] at first examination). One reviewer drew regions of interest around psoas muscles at L3 to measure cross-sectional area. Multiple linear mixed-effect modeling was performed to evaluate the association between muscle mass and the covariates over time.

RESULTS: The 24 patients underwent a total of 129 abdominal CT or MRI examinations. Median duration of mTOR inhibition at last examination was 106 months (range, 1310-3717 days). There was no significant association between the duration of mTOR inhibitor therapy and psoas muscle area on multiple linear mixed-effect modeling (P = .055); however, patient height and height squared were significant predictors of psoas area (P = .014 and P < .0001, respectively).

CONCLUSION: Duration of mTOR inhibition in TSC was not significantly associated with a decrease in psoas muscle area, suggesting that chronic mTOR inhibition is not associated with sarcopenia.Keywords: CT, MR-Imaging, Pediatrics© RSNA, 2020.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Raab C, Gilligan LA, Trout AT, et al. mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI. Radiol Imaging Cancer. 2020. PMID: 33778734. doi:10.1148/rycan.2020190091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。